CEO Lawrence Blatt (Aligos)
With a potential $458M per target payday, Aligos teams up with Merck hoping to reverse biotech's recent NASH maladies
Just a few months after going public with a $150 million IPO, Aligos Therapeutics $ALGS is aiming to further capitalize on its momentum with a new NASH deal.
The biotech has teamed up with Merck to try to develop oligonucleotide therapies for the disease, a slate that could be worth up to $458 million in milestones per target. Aligos and Merck did not disclose how much would be paid upfront, but noted there would be another cash payment once the pair decides on a second target.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
